22 May 2013 - Changes to GSK Manufacturing Site in Melbourne

 

22 May 2013 - Changes to GSK Manufacturing Site in Melbourne

GlaxoSmithKline (GSK) Australia is intending to close the tablet packaging part of the business at the Melbourne site in Boronia as part of a business transformation. 

It is estimated that 120 jobs will be lost through the transformation however any redundancy will not come into effect immediately as the process will take some time to account for regulatory requirements of affected markets. 

"We will support our impacted employees throughout the process. While this will be difficult, we must focus on our strengths. We have a strong capability in higher technology manufacturing and will build this side of the business," Troy Webb Boronia Site Director said. 

The Boronia manufacturing facility is renowned for Rotacaps, a distribution device for respiratory medicines that the company is investing in to support patients in emerging markets, and Blow Fill Seal, a high quality container for sterile liquid medicines. 

"Despite continuing challenges in the operating environment in Australia, our vision is to be the GSK centre of excellence worldwide for supplying low cost unit dose, blow fill seal and dry powder inhalation medicines," Troy said. 

The GSK site in Boronia currently employees 363 people. 

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a mission to improve the quality of human life. In Australia we have delivered the highest quality medicines, vaccines and over-the-counter healthcare products since 1886. We contribute to Australia's economy through new approaches to agriculture and manufacturing, and by investing in local research and development. For more information visit www.gsk.com.au 
 

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.